/
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients.
The business is unprofitable at the operating level (-3228.83% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 23.2% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$201M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$4M
▼ -23.2% YoY
Net Income (TTM)
-$225M
▲ +27.5% YoY
Op. Margin
-5947.90%
▲ +153.5pp YoY
ROIC
-42.59%
▲ +114.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$206M
▼ -70.1% YoY
Op. Cash Flow (TTM)
-$197M
▼ -72.3% YoY
Net Debt
-$579M
Net Cash Position
Cash & Equiv.
$583M
Continue Research